Assess the Long-term Safety and Effecticeness of Osilodrostat in Patients with Endogenous Cushing’s Syndrome

Overview

About this study

The primary purpose of this study is to further document the long-term safety and tolerability profile of osilodrostat in routine clinical practice over a 3-year follow-up period when administered as monotherapy or in combination with other therapies in patients with endogenous Cushing’s Syndrome (CS).

Participation eligibility

Participant eligibility includes age, gender, type and stage of disease, and previous treatments or health concerns. Guidelines differ from study to study, and identify who can or cannot participate. There is no guarantee that every individual who qualifies and wants to participate in a trial will be enrolled. Contact the study team to discuss study eligibility and potential participation.

Two cohorts of patients are planned to be enrolled in the study:

“New user”: patients starting osilodrostat at study entry;
“Prior user”: patients that have started osilodrostat any time prior to study entry.

InclusIon Criteria:

Written informed consent obtained prior to registration of any patient data.
Male or female patients, aged 18 years or older
Diagnosed with endogenous Cushing's Syndrome (CS).
Treated with osilodrostat. Treatment with osilodrostat can either be initiated at the first visit of the study or can have been initiated before screening.

Exclusion Criteria:

Patients with exogenous CS.
Patients with Pseudo CS.
Patients participating in an interventional clinical trial with an investigational drug.

Eligibility last updated 5/9/22. Questions regarding updates should be directed to the study team contact.

Participating Mayo Clinic locations

Study statuses change often. Please contact the study team for the most up-to-date information regarding possible participation.

Mayo Clinic Location	Status	Contact
Rochester, Minn. Mayo Clinic principal investigator Irina Bancos, M.D., M.S.	Closed for enrollment	Contact information: Vanessa Fell M.A. (507) 266-6068 Fell.Vanessa@mayo.edu

Mayo Clinic Location

Status

Contact

Rochester, Minn.

Mayo Clinic principal investigator

Irina Bancos, M.D., M.S.

Closed for enrollment

Contact information:

Vanessa Fell M.A.

(507) 266-6068

Fell.Vanessa@mayo.edu

More information

Publications

Publications are currently not available

Clinical Trials